United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease

United Therapeutics Corp (NASDAQ: UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with chronic obstructive pulmonary disease.